INTRODUCTION
Over the past decades, the prevalence of inflammatory bowel disease (IBD) has surged globally. It is commonly believed that IBD occurs mainly in Western countries, with more than 2 million people in North America and more than 3.2 million people in Europe. 1 However, since the beginning of the 21st century, the incidence of IBD has increased substantially in Asia. From 1990 to 2019, the age-standardized prevalence rate of IBD has risen dramatically, from 29.81 to 39.37 (per 100,000 people). 2 A study in the United States showed that the annual cost of IBD nursing exceeds 10 billion dollars. 3 IBD not only reduces the quality of life of patients but also predisposes them to a variety of malignancies, especially colorectal cancer. Several studies have shown a potential correlation between IBD and hematologic malignancy. 4 , 5
Hematologic malignancies are a group of diseases of the hematopoietic hierarchy, including leukemia, lymphoma, and multiple myeloma. They have the highest morbidity and mortality rates. Repeated virus infections and chronic exposure to organic solvents or heavy metals are all risk factors for hematologic malignancies. Several studies have reported that the use of immunosuppressive therapy may increase the risk of malignancies in patients with IBD. 6
Previous meta-analysis suggested that hematologic malignancies were more likely to occur in patients with IBD, but the result showed borderline significance. 7 For specific types of hematologic malignancies, the results of research vary and deserve further analysis and exploration. 8 In addition, with the development of research, the therapeutic agents of IBD have changed, and more and more biologics have been adopted. At the same time, cohort studies on the correlation between IBD and hematologic malignancies are constantly being updated. Especially in Asia, cohort studies are increasing. Due to genetic and environmental factors, the specific profile of malignancies in Asian patients with IBD may vary from that of Western countries. Based on the above, it is necessary to update the meta-analysis and make a more detailed subgroup analysis in terms of IBD type, hematologic malignancy type, pharmacotherapy, age, and geographical factors. In this study, a meta-analysis was conducted to investigate the correlation between IBD and hematologic malignancies in studies conducted after 2000.
MATERIALS AND METHODS
1. Literature search strategy
This study was conducted in line with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) and MOOSE (Meta-analysis of Observational Studies in Epidemiology) reporting guidelines. Only cohort studies on the relationship between patients with IBD and hematologic malignancies were selected for this study and were based on publicly procurable data, all of which were extracted from previously ethically approved studies. The protocol for this study had been registered in the International Prospective Register of Systematic Reviews, with the registration number CRD42024462331.
Two investigators independently conducted a systematic and comprehensive literature retrieval in PubMed, Web of Science, Embase, and Cochrane Library databases to identify all published articles. The search terms were used as follows: (hematological cancers OR hematologic malignancies OR hematologic malignant tumors OR leukemia OR multiple myeloma OR lymphoma OR lymphoproliferative OR myeloproliferative) AND (ulcerative colitis OR inflammatory bowel disease OR Crohn's disease OR IBD OR UC OR CD). The retrieval period was from January 2000 to June 2023. In addition, a manual search of references to relevant literature was conducted to avoid the omission of any potential articles.
2. Inclusion and exclusion criteria
According to the PICOS principle, the inclusion criteria of the articles were as follows: (1) population: people without hematologic malignancies or related high-risk factors; (2) exposure: patients diagnosed with IBD; (3) control: people who did not suffer from IBD; (4) outcome: the incidence of hematologic malignancies; or (5) study design: the cohort studies. The exclusion criteria were as follows: (1) full texts were not available; (2) articles were published before 2000; (3) articles were not prepared in English; (4) the patients had developed hematologic malignancies before the diagnosis of IBD was made; or (5) when encountering different articles with the same source of the cohort data, more comprehensive or newer updated studies were included.
3. Outcome measures
The main outcome indicator was the incidence of hematologic malignancies in patients with IBD during the follow-up. Malignant hematologic diseases include lymphoma, leukemia, multiple myeloma, and so on.
4. Data extraction
Two investigators independently extracted data from all eligible studies, and a third adjudicator would review and confirm the ultimate results. The following information was collected: (1) research characteristics (authors, publication year, duration of cohorts, and countries); (2) patient characteristics (number of patients, age, gender, type of IBD, ulcerative colitis (UC) or Crohn's disease (CD) phenotypes, pharmacotherapy, and regions); or (3) the specific tumor types of hematologic malignancies and their corresponding overall incidence rates.
5. Quality assessment
Two investigators evaluated the quality independently. When there was a disagreement, a third investigator could be introduced to resolve the contradiction. We used the Newcastle-Ottawa Scale (NOS) to evaluate the potential risk of bias. 9 NOS evaluates the risk of bias by evaluating the quality of the cohort study in terms of selection, comparability, and outcomes. In the process of evaluation, each aspect is assigned a score out of a total score of 9. The score of each aspect can be modified according to the specific situation of the study, making the NOS more suitable for evaluating specific studies. Articles with a score of 0–6 are defined as low quality, and articles with a score of 7–9 are regarded as high quality.
6. Statistical analysis
Statistical analyses were carried out using Stata 12.0 (Stata Statistical Software for data science, College Station, TX, USA). Standardized incidence ratio (SIR) with 95% confidence intervals (CI) was calculated to evaluate the incidence of hematologic malignancies in IBD patients. Heterogeneity across studies was estimated by the chi-square test and quantified by I 2 statistics, 10 with I 2 ≤50% representing low heterogeneity, 50%<I 2 ≤75% representing moderate heterogeneity, and I 2 >75% representing high heterogeneity. Considering the potential and inevitable heterogeneity among included articles, such as ethnicity, IBD type, and hematologic malignancy type, all analyses in this study were performed using a random-effects model to improve the credibility of the results. 11 Additionally, subgroup analyses were conducted to explore the sources of heterogeneity, and sensitivity analysis was used to test the stability of the results. The publication bias was evaluated by Egger test. 12 p<0.05 was considered t statistically significant in bilateral tests.
RESULTS
1. Studies selection
In this study, a total of 8,619 studies were retrieved from four databases. After eliminating duplicate records, 5,514 articles remained. For articles obtained without other sources, 5,427 unrelated records were eliminated through titles and abstracts, leaving 87 studies. By manually scrutinizing the full texts of 87 studies, 67 studies were excluded for the following reasons: 18 were duplicated database sources, 29 had nonsignificant results, nine were without available data, 11 were non-cohort studies, and 20 studies were finally included. 8 , 13 - 31 The specific results are shown in Fig. 1 .
2. Characteristics of the included studies
From 2000 to 2023, there were 20 cohort studies to observe the incidence of hematologic malignancies in patients with IBD and to compare it with the non-IBD population. These 20 studies involved 756,377 subjects from nine national cohorts and 11 regional cohorts covering five continents, including five in Asia (China, South Korea, and Japan), three in North America (USA), and 11 in Europe (Hungary, Netherlands, Denmark, Finland, Switzerland, Italy, Swiss, Norway, France, Britain, and Sweden). The earliest cohort started in 1940 and the latest cohort ended in 2019. The mean follow-up period of all studies ranged from 3 years to 19.9 years. Of these 20 studies, four reported the proportion of thiopurine used in IBD patients and four reported the steroid used in patients with IBD. Diseases can be classified into different phenotypes according to the different positions of the diseases in the Montreal classification. Seven studies reported the proportion of patients with UC patients in the four phenotypes (proctitis, left-sided colitis, extensive colitis, and unknown), and eight studies reported four phenotypes in CD patients (terminal ileum, colonic, ileocolonic, and upper gastrointestinal). The details are shown in Table 1 and Supplementary Table 1 .
3. Quality assessment
NOS was used to evaluate the quality of 20 cohort studies. The scoring results showed that all the articles used in this meta-study scored ≥6, demonstrating the high quality of the articles ( Supplementary Table 2 ).
4. Analysis of the primary result
Combining the statistical results of the 20 cohort studies, the incidence of hematologic malignancies was higher in patients with IBD compared to the non-IBD population, with an SIR of 3.05 (95% CI, 1.77 to 5.27; p<0.001). However, this result had high heterogeneity with I 2 =94% ( Fig. 2 ).
5. Subgroup analysis
Depending on the specific type of IBD disease, IBD patients can be divided into UC patients and CD patients. Compared to the non-IBD population, UC patients had a higher incidence of hematologic malignancies (SIR=2.29, p=0.05), and similarly, CD patients had a higher incidence of hematologic malignancies (SIR=3.56, p=0.005) ( Fig. 3 ).
Hematologic malignancies can be divided into non-Hodgkin's lymphoma (NHL), Hodgkin's lymphoma (HL), and leukemia. The incidence of different types of hematologic malignancies was higher in IBD patients compared to controls, with the SIR of 1.70 (95% CI, 1.14 to 2.54; p=0.01) for NHL, 3.47 (95% CI, 1.56 to 7.73; p=0.002) for HL and 3.69 (95% CI, 2.14 to 6.37; p<0.001) for leukemia ( Fig. 4 ).
In terms of the use of therapeutic drugs, the three groups, including immunomodulators, anti-tumor necrosis factor (TNF) and thiopurines, encompassed the outcomes of IBD patients who had utilized the respective medications, irrespective of whether the administration was as monotherapy or as part of a combination therapy regimen. The incidence of hematologic malignancies was higher in IBD patients treated with immunomodulators compared to the control group (SIR=4.46, p<0.001) ( Fig. 5 ). According to the specific drug type, the SIR for IBD patients who used anti-TNF drugs was 5.10 (95% CI, 3.52 to 7.39; p<0.001), while the SIR for IBD patients who used thiopurine was 3.80 (95% CI, 2.46 to 5.87; p<0.001) ( Table 2 ).
Compared with the non-IBD population, the incidence of hematologic malignancies was higher in patients with IBD, both younger than 40 years old (SIR=2.49, p<0.001) and older than 40 years old (SIR=2.44, p=0.02). Geographically, the incidence of hematologic malignancies was higher in IBD patients than in the non-IBD population, either in Asia (SIR=3.60, p<0.001), Europe (SIR=2.78, p=0.009) or the United States (SIR=2.50, p=0.001) ( Table 2 ).
6. Publication bias and sensitivity analysis
The Egger test in Stata12.0 was applied to visually measure publication bias, and the result was p=0.768, suggesting no obvious publication bias ( Supplementary Fig. 1 ). By excluding individual studies one by one, the sensitivity of the meta-analysis of the correlation between IBD and hematologic malignancy was analyzed. The results suggested that the combined statistical results were stable ( Supplementary Fig. 2 ).
DISCUSSION
Combined with the statistical results of 20 cohort studies, the incidence of hematologic malignancies is higher in patients with IBD compared to the non-IBD population, a phenomenon observed in both UC and CD patients, with a higher incidence in CD. Among hematologic malignancies, IBD patients were at higher risk of developing NHL, HL, and leukemia. The incidence of hematologic malignancies in IBD patients treated with immunomodulators. The results were consistent across geographical environments. To summarize, there is a potential correlation between IBD and hematologic malignancies.
Due to the immune imbalance and chronic inflammation in the intestines in IBD patients, there can be changes in their immune components, which in turn affect the immune response of tumors. For example, human leukocyte antigen G (HLA-G) is a potent immunosuppressive molecule that binds to immunosuppressive receptors. Expression of HLA-G induced by microenvironment cues, including cytokines, may participate in anti-inflammatory immune responses and malignant transformation. The expression of HLA-G during chronic inflammation leads to the growth of transformed cells beyond the recognition range by host immune surveillance. 32 The findings show that the risk of malignant tumor development is increased in the case of intestinal inflammatory diseases, such as UC and CD. At the same time, the report shows that the increase of HLA-G is common in hematologic malignancies. In a study by Martín-Lorenzo et al. , 33 HLA-G was also found to increase significantly in B-cell chronic lymphocytic leukemia. HLA-G is preferentially detected in tumor tissues but rarely in adjacent normal tissues, suggesting a specific correlation with tumor growth and progression. Aberrant expression of HLA-G in cancer has been associated with the establishment of anti-tumor immune responses and tumor escape. Studies have shown that in HL patients, 54% of HLA-G protein is up-regulated, suggesting that increased expression of HLA-G proteins by tumor cells may be an immune escape mechanism. 33
Patients with IBD are chronically exposed to an inflammatory environment in the body that may lead to abnormal gene mutations, which in turn increase the risk of hematologic malignancies. Clonal hematopoiesis (CH) is a precancerous lesion, a somatic mutation in hematopoietic stem cells and progenitor cells that increases the risk of hematologic malignancies. 34 There is growing evidence of a correlation between inflammation and CH. 35 Its presence in the context of IBD has been well established. Several studies have detected multiple mutations in several genes in patients with IBD who exhibit one or more mutations. Chronic infections and inflammatory responses caused by intestinal dysfunction may promote the selection of CH-related DNMT3A gene mutation through interferon-γ signal transduction induced by these diseases. 35 The inflammatory environment may selectively induce the development of CH-specific mutations, which will underlie the biological basis of hematologic malignancies. 36
The imbalance of the intestinal flora and the disruption of the mucosal barriers may play an important role in the development of hematologic malignancies in patients with IBD. 37 Some host bacteria are directly involved in promoting oxidative stress, leading to DNA damage and consequently cancer. 38 , 39 Studies have shown that the microbiota-intestinal-lymphoma axis is one of the pathways of lymphoma. 40 The most common site of primary extranodal lymphoma is the gastrointestinal tract and a large number of lymphoma patients have documented intestinal dysbiosis. 41 It has been proven that Helicobacter pylori is a risk factor in more than 90% of cases of gastric mucosa-associated lymphoid tissue lymphoma, 42 and the same pathological pattern exists in mice with chronic H. pylori infection, especially Felis H. pylori . 43 In addition, studies have shown that bacteria such as Campylobacter jejuni , Chlamydia psittaci , and Borrelia berenii are also involved in the development of human lymphoma. 33 It has been found that a series of bacteria causing intestinal infections, such as Campylobacter , 44 will increase the risk of IBD, and bacterial infections recur throughout the course of the disease in IBD patients. Therefore, bacteria may play an important role in the process of hematologic malignancies in patients with IBD.
Through the above potential mechanisms, IBD patients may be at increased risk of developing hematologic malignancies, including leukemia and lymphoma. In this study, patients with IBD had the highest incidence of leukemia compared to NHL and HL. One possible reason for this is that patients with IBD have genes that are prone to mutate abnormally in response to factors such as inflammation, and the resulting CH is more likely to evolve into myeloid malignant tumors. The clonal hematopoietic population eventually progresses to myelodysplastic syndrome or acute myeloid leukemia, whereas the malignant tumor of the lymphatic system is less likely to develop into leukemia. 45 The higher risk of developing HL in patients with IBD compared to NHL may be related to the role of inflammatory factors in HL. For example, the up-regulation of the HLA-G protein mentioned above is more pronounced in patients with HL. In addition, the choice of therapeutic agents for IBD may also affect the types of hematologic malignancies to some extent. The thiopurine mentioned below makes lymphoma relatively common.
Immunosuppressants and biological agents are increasingly being used to treat IBD, making it necessary to consider the risks of therapeutic drugs. The present study found that patients who used thiopurine or anti-TNF-α drugs have an increased risk of hematologic malignancies. Some studies believed that TNF-α is a cytokine involved in systemic inflammation and immune system regulation, and that inhibition of TNF-α favors the process of tumor formation. 46 Two experimental studies support the view that anti-TNF promotes tumor formation, either alone or in combination with thiopurine, and contributes to the development of lymphoma. 47 , 48 One study found that anti-TNF could inhibit the activity of natural killer cells and harm anti-lymphoma activity in vitro . 47 Another study showed that the lymphoma-like transformation driven by the Epstein-Barr virus was amplified by anti-TNF and 6-mercaptopurine in the lymphoma model in vitro . 48
This study found that the incidence of hematologic malignancies in CD patients was higher than that in UC patients. The reason may be that UC lesions are mainly located in the large intestine, and retrograde development may also involve the entire colon and the terminal ileum. However, CD lesions may involve both the terminal ileum and the adjacent right colon at the same time, or only the small intestine or colon, as well as the oral cavity, esophagus, stomach, and duodenum. Lesions that are segmental or jumping, with extensive inflammatory involvement, tend to be more severe, which also causes heavier dosages and duration of treatment in patients with CD than in patients with UC. In addition, CD patients are exposed to higher levels of harmful diagnostic radiation from repeated radiography, which may also be related to their increased risk of developing hematologic malignancies. 49
This study found that, compared to other regions, Asian patients with IBD have a higher risk of developing hematologic malignancies. It is generally recognized that environmental pollution is often more severe in developing countries due to industrial and economic factors, potentially increasing risks in Asian regions. Studies have shown that hematologic malignancies are positively correlated with factors such as ultraviolet exposure and pesticide use. 50 , 51 Moreover, anti-inflammatory dietary patterns are more common in Europe than in Asia, which may play a role in the hematologic malignancy risks among Asian IBD patients. Mediterranean diet is considered a beneficial diet for patients with IBD due to its modulating effect on inflammation. The research shows that the high score of the Mediterranean diet is negatively correlated with the risk and progression of IBD. 52 Therefore, the areas dominated by the Mediterranean diet may inhibit the development of inflammation during the process of IBD because of its anti-inflammatory effect, thereby reducing the occurrence of hematologic malignancies.
This study is based on cohort studies with a high degree of confidence. In contrast to a previous study, which had merely briefly touched upon the incidence of different hematologic malignancy types in patients with IBD subtypes, 7 our study delves into a comprehensive analysis of the incidence of different hematologic malignancy types in IBD patients, as well as the impact of other factors such as pharmacotherapy, age and region on the risk of hematologic malignancies. This study endeavored to offer fresh perspectives through a more thorough analysis, encompassing more nuanced subgroup analyses, and has yielded more pronounced results. The limitation is that this study does not have enough data to study the influence of the dose effect of drugs on the occurrence of hematologic malignancies in IBD patients and the impact of monotherapy and combination therapy on the incidence of hematologic malignancies. At the same time, due to the lack of data, it was not possible to evaluate the influence of follow-up time on the occurrence of hematologic malignancies in IBD patients. In addition, the high heterogeneity (I 2 =94% in Fig. 2 ) can lead to decreased credibility of the statistical results.
In conclusion, this meta-analysis provides the latest information on the incidence of hematologic malignancies in patients with IBD. The incidence of hematologic malignancies is higher in patients with IBD than in the non-IBD population, including NHL, HL, and leukemia. This relationship may be influenced by factors such as the type of IBD, pharmacotherapy, and other variables. Additionally, more large multicenter cohort studies are needed to confirm the phenomenon.
CONFLICTS OF INTEREST
No potential conflict of interest relevant to this article was reported.
AUTHOR CONTRIBUTIONS
Study concept and design: L.T. Data acquisition: X.Z. Data analysis and interpretation: Q.Z. Drafting of the manuscript: Q.Z. Critical revision of the manuscript for important intellectual content: D.W. Statistical analysis: Z.X. Obtained funding: L.T. Administrative, technical, or material support; study supervision: J.R. Approval of final manuscript: all authors.
DATA AVAILABILITY STATEMENT
The datasets supporting this article’s conclusions are included within the article and its additional files.
SUPPLEMENTARY MATERIALS
Supplementary materials can be accessed at https://doi.org/10.5009/gnl240119 .
REFERENCES
1 Ananthakrishnan AN Kaplan GG Ng SC 2020 Changing global epidemiology of inflammatory bowel diseases: sustaining health care delivery into the 21st century Clin Gastroenterol Hepatol 18 1252 1260 10.1016/j.cgh.2020.01.028 32007542
2 Chen X Xiang X Xia W 2023 Evolving trends and burden of inflammatory bowel disease in Asia, 1990-2019: a comprehensive analysis based on the global burden of disease study J Epidemiol Glob Health 13 725 739 10.1007/s44197-023-00145-w f770934772e54f58b0047664d4d2f5c8 37653213 PMC10686927
3 Park KT Ehrlich OG Allen JI 2020 The cost of inflammatory bowel disease: an initiative from the Crohn's & Colitis Foundation Inflamm Bowel Dis 26 1 10 10.1093/ibd/izz104 31112238 PMC7534391
4 Komaki Y Komaki F Yamada A Micic D Ido A Sakuraba A 2021 Risk of cancers in patients with pediatric inflammatory bowel diseases: a systematic review and meta-analysis J Pediatr 229 102 117 10.1016/j.jpeds.2020.08.087 32898579
5 Wheat CL Clark-Snustad K Devine B Grembowski D Thornton TA Ko CW 2016 Worldwide incidence of colorectal cancer, leukemia, and lymphoma in inflammatory bowel disease: an updated systematic review and meta-analysis Gastroenterol Res Pract 2016 1632439 10.1155/2016/1632439 37adf9e470af40d18826e8b535890ccc 27293427 PMC4884856
6 Lopez A Beaugerie L Peyrin-Biroulet L 2014 Thiopurines and myeloid disorders: is more caution needed when treating inflammatory bowel disease patients? Expert Rev Clin Immunol 10 1563 1565 10.1586/1744666X.2014.977261 25362886
7 Lo B Zhao M Vind I Burisch J 2021 The risk of extraintestinal cancer in inflammatory bowel disease: a systematic review and meta-analysis of population-based cohort studies Clin Gastroenterol Hepatol 19 1117 1138 10.1016/j.cgh.2020.08.015 32801010
8 Taborelli M Sozzi M Del Zotto S 2020 Risk of intestinal and extra-intestinal cancers in patients with inflammatory bowel diseases: a population-based cohort study in northeastern Italy PLoS One 15 e0235142 10.1371/journal.pone.0235142 b15c69d17d8a4cff82548aaf0b493a16 32574216 PMC7310697
9 Stang A 2010 Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses Eur J Epidemiol 25 603 605 10.1007/s10654-010-9491-z 20652370
10 Pandis N 2016 The chi-square test Am J Orthod Dentofacial Orthop 150 898 899 10.1016/j.ajodo.2016.08.009 27871717
11 Kanters S 2022 Fixed- and random-effects models Methods Mol Biol 2345 41 65 10.1007/978-1-0716-1566-9_3 34550583
12 Lin L Chu H 2018 Quantifying publication bias in meta-analysis Biometrics 74 785 794 10.1111/biom.12817 29141096 PMC5953768
13 Ashworth LA Billett A Mitchell P Nuti F Siegel C Bousvaros A 2012 Lymphoma risk in children and young adults with inflammatory bowel disease: analysis of a large single-center cohort Inflamm Bowel Dis 18 838 843 10.1002/ibd.21844 21887728
14 Lakatos PL Lovasz BD David G 2013 The risk of lymphoma and immunomodulators in patients with inflammatory bowel diseases: results from a population-based cohort in Eastern Europe J Crohns Colitis 7 385 391 10.1016/j.crohns.2012.06.011 22766526
15 Yano Y Matsui T Hirai F 2013 Cancer risk in Japanese Crohn's disease patients: investigation of the standardized incidence ratio J Gastroenterol Hepatol 28 1300 1305 10.1111/jgh.12189 23488881
16 Yadav S Singh S Harmsen WS Edakkanambeth Varayil J Tremaine WJ Loftus EV 2015 Effect of medications on risk of cancer in patients with inflammatory bowel diseases: a population-based cohort study from Olmsted County, Minnesota Mayo Clin Proc 90 738 746 10.1016/j.mayocp.2015.03.024 25963756 PMC4458158
17 van den Heuvel TR Wintjens DS Jeuring SF 2016 Inflammatory bowel disease, cancer and medication: cancer risk in the Dutch population-based IBDSL cohort Int J Cancer 139 1270 1280 10.1002/ijc.30183 27170593
18 Wang LH Yang YJ Cheng WC Wang WM Lin SH Shieh CC 2016 Higher risk for hematological malignancies in inflammatory bowel disease: a nationwide population-based study in Taiwan Am J Gastroenterol 111 1313 1319 10.1038/ajg.2016.239 27296944
19 So J Tang W Leung WK 2017 Cancer risk in 2621 Chinese patients with inflammatory bowel disease: a population-based cohort study Inflamm Bowel Dis 23 2061 2068 10.1097/MIB.0000000000001240 28991855
20 Malham M Jakobsen C Paerregaard A Virta LJ Kolho KL Wewer V 2019 The incidence of cancer and mortality in paediatric onset inflammatory bowel disease in Denmark and Finland during a 23-year period: a population-based study Aliment Pharmacol Ther 50 33 39 10.1111/apt.15258 31069829
21 Scharl S Barthel C Rossel JB 2019 Malignancies in inflammatory bowel disease: frequency, incidence and risk factors-results from the Swiss IBD Cohort Study Am J Gastroenterol 114 116 126 10.1038/s41395-018-0360-9 30333538
22 Zhang H Zhang M Chen X 2022 Risk of malignancy in patients with inflammatory bowel disease: a population-based cohort study from China Int J Cancer 150 1770 1778 10.1002/ijc.33932 35037241
23 Olén O Smedby KE Erichsen R 2023 Increasing risk of lymphoma over time in Crohn's disease but not in ulcerative colitis: a Scandinavian cohort study Clin Gastroenterol Hepatol 21 3132 3142 10.1016/j.cgh.2023.04.001 37061104
24 Yu J Refsum E Wieszczy P 2023 Risk of malignant lymphomas in patients with inflammatory bowel disease: a population-based cohort study BMJ Open Gastroenterol 10 e001037 10.1136/bmjgast-2022-001037 eea55344b0ab45ea9e4dc2309f3850ea 37142293 PMC10163486
25 Lopez A Mounier M Bouvier AM 2014 Increased risk of acute myeloid leukemias and myelodysplastic syndromes in patients who received thiopurine treatment for inflammatory bowel disease Clin Gastroenterol Hepatol 12 1324 1329 10.1016/j.cgh.2014.02.026 24582568
26 Chiorean MV Pokhrel B Adabala J Helper DJ Johnson CS Juliar B 2011 Incidence and risk factors for lymphoma in a single-center inflammatory bowel disease population Dig Dis Sci 56 1489 1495 10.1007/s10620-010-1430-z 20953706
27 Beaugerie L Brousse N Bouvier AM 2009 Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study Lancet 374 1617 1625 10.1016/S0140-6736(09)61302-7 19837455
28 Palli D Trallori G Bagnoli S 2000 Hodgkin's disease risk is increased in patients with ulcerative colitis Gastroenterology 119 647 653 10.1053/gast.2000.16487 10982757
29 Lewis JD Bilker WB Brensinger C Deren JJ Vaughn DJ Strom BL 2001 Inflammatory bowel disease is not associated with an increased risk of lymphoma Gastroenterology 121 1080 1087 10.1053/gast.2001.28703 11677199
30 Jung JM Kim YJ Chang SE Lee MW Won CH Lee WJ 2023 The risk of lymphoproliferative disorders and skin cancers in patients with psoriasis and inflammatory bowel disease administered biologics Dermatol Ther 2023 9224241 10.1155/2023/9224241
31 Farrell RJ Ang Y Kileen P 2000 Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low Gut 47 514 519 10.1136/gut.47.4.514 10986211 PMC1728075
32 Yan WH 2010 HLA-G expression in hematologic malignancies Expert Rev Hematol 3 67 80 10.1586/ehm.09.72 21082935
33 Martín-Lorenzo A Hauer J Vicente-Dueñas C 2015 Infection exposure is a causal factor in B-cell precursor acute lymphoblastic leukemia as a result of Pax5-inherited susceptibility Cancer Discov 5 1328 1343 10.1158/2159-8290.CD-15-0892 26408659
34 Ye B Sheng Y Zhang M Hu Y Huang H 2022 Early detection and intervention of clonal hematopoiesis for preventing hematological malignancies Cancer Lett 538 215691 10.1016/j.canlet.2022.215691 35469959
35 Cumbo C Tarantini F Zagaria A 2022 Clonal hematopoiesis at the crossroads of inflammatory bowel diseases and hematological malignancies: a biological link? Front Oncol 12 873896 10.3389/fonc.2022.873896 f839630c27d04da8aaad77d31af5a75d 35494055 PMC9039212
36 Kaner J Desai P Mencia-Trinchant N Guzman ML Roboz GJ Hassane DC 2020 Clonal hematopoiesis and premalignant diseases Cold Spring Harb Perspect Med 10 a035675 10.1101/cshperspect.a035675 31615870 PMC7117948
37 Qiu P Ishimoto T Fu L Zhang J Zhang Z Liu Y 2022 The gut microbiota in inflammatory bowel disease Front Cell Infect Microbiol 12 733992 10.3389/fcimb.2022.733992 f4ac07952d64450fbdb617ceda547b24 35273921 PMC8902753
38 Reddy BS Mangat S Weisburger JH Wynder EL 1977 Effect of high-risk diets for colon carcinogenesis on intestinal mucosal and bacterial beta-glucuronidase activity in F344 rats Cancer Res 37 3533 3536 908005
39 Knasmüller S Steinkellner H Hirschl AM Rabot S Nobis EC Kassie F 2001 Impact of bacteria in dairy products and of the intestinal microflora on the genotoxic and carcinogenic effects of heterocyclic aromatic amines Mutat Res 480-481 129 138 10.1016/S0027-5107(01)00176-2 11506806
40 Shi Z Zhang M 2021 Emerging roles for the gut microbiome in lymphoid neoplasms Clin Med Insights Oncol 15 11795549211024197 10.1177/11795549211024197 0613819cdd2b46dca73458293a3458b9 34211309 PMC8216388
41 Wotherspoon AC Ortiz-Hidalgo C Falzon MR Isaacson PG 1991 Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma Lancet 338 1175 1176 10.1016/0140-6736(91)92035-Z 1682595
42 Ferrero RL Avé P Radcliff FJ Labigne A Huerre MR 2000 Outbred mice with long-term Helicobacter felis infection develop both gastric lymphoid tissue and glandular hyperplastic lesions J Pathol 191 333 340 10.1002/1096-9896(2000)9999:9999<::AID-PATH619>3.0.CO;2-H 10878557
43 Enno A O'Rourke JL Howlett CR Jack A Dixon MF Lee A 1995 MALToma-like lesions in the murine gastric mucosa after long-term infection with Helicobacter felis: a mouse model of Helicobacter pylori-induced gastric lymphoma Am J Pathol 147 217 222 7604881 PMC1869885
44 Dai C Huang YH Jiang M Sun MJ 2020 Nonclostridium difficile enteric infection and the risk of developing inflammatory bowel disease: a systematic review and meta-analysis Saudi J Gastroenterol 26 299 305 10.4103/sjg.SJG_231_20 6c6249aa096e4b2c819852b5b6594986 33154203 PMC8019142
45 Michaux M Chan JM Bergmann L Chaves LF Klinkenberg B Jacobson K 2023 Spatial cluster mapping and environmental modeling in pediatric inflammatory bowel disease World J Gastroenterol 29 3688 3702 10.3748/wjg.v29.i23.3688 37398882 PMC10311617
46 Aggarwal BB Gupta SC Kim JH 2012 Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey Blood 119 651 665 10.1182/blood-2011-04-325225 22053109 PMC3265196
47 Nocturne G Boudaoud S Ly B Pascaud J Paoletti A Mariette X 2017 Impact of anti-TNF therapy on NK cells function and on immunosurveillance against B-cell lymphomas J Autoimmun 80 56 64 10.1016/j.jaut.2017.02.001 28214146
48 Levhar N Ungar B Kopylov U 2020 Propagation of EBV-driven lymphomatous transformation of peripheral blood B cells by immunomodulators and biologics used in the treatment of inflammatory bowel disease Inflamm Bowel Dis 26 1330 1339 10.1093/ibd/izaa065 32322878
49 Brenner DJ Hall EJ 2007 Computed tomography: an increasing source of radiation exposure N Engl J Med 357 2277 2284 10.1056/NEJMra072149 18046031
50 Roingeard C Monnereau A Goujon S Orazio S Bouvier G Vacquier B 2021 Passive environmental residential exposure to agricultural pesticides and hematological malignancies in the general population: a systematic review Environ Sci Pollut Res Int 28 43190 43216 10.1007/s11356-021-14789-3 34165744
51 Coste A Goujon S Boniol M 2015 Residential exposure to solar ultraviolet radiation and incidence of childhood hematological malignancies in France Cancer Causes Control 26 1339 1349 10.1007/s10552-015-0629-x 26169300
52 Tian Z Zhuang X Zhao M 2021 Index-based dietary patterns and inflammatory bowel disease: a systematic review of observational studies Adv Nutr 12 2288 2300 10.1093/advances/nmab069 34157069 PMC8634451